CANDEL THERAPEUTICS, INC.

Analyst Reco. Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
8.9 ^USD	+3.25%		+14.10%	+505.44%

May. 30	FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma	MT
May. 30	Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating	23-03-31	MT
UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating	22-12-09	MT
Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating	22-12-07	MT
HC Wainwright Starts Candel Therapeutics at Buy With $11 Price Target	22-12-02	MT
BMO Capital Adjusts Candel Therapeutics' Price Target to $12 from $18, Keeps Outperform Rating	22-03-31	MT
BMO Initiates Candel Therapeutics With Outperform Rating, $18 Price Target	21-11-18	MT
Candel Therapeutics : Shares Rise After Analyst Recommendations	21-08-23	MT
CANDEL THERAPEUTICS : Credit Suisse Starts Candel Therapeutics at Outperform with $15 PT, Notes Potential for Improved Investor Sentiment, Valuation	21-08-23	MT
CANDEL THERAPEUTICS : UBS Starts Candel Therapeutics at Buy With $9 Price Target	21-08-23	MT
CANDEL THERAPEUTICS : Jefferies Starts Candel Therapeutics at Buy With $22 Price Target	21-08-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer